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Case selectionAbstract The complete regeneration of the periodontal tissues following periodontal disease remains
an unmet challenge, and has presented clinicians with a remarkably difficult clinical challenge to solve
given the extensive research in this area and our current understanding of the biology of the periodon-
tal tissues. In particular as clinicians we look for treatments that will improve the predictability of the
procedure, improve the magnitude of the effect of treatment, and perhaps most importantly in the
long termwould extend the indications for treatment beyond the need for single enclosed bony defects
to allow for suprabony regeneration, preferably with beneficial effects on the gingival soft tissues. A
rapid development in both innovative methods and products for the correction of periodontal defi-
ciencies have been reported during the last three decades. For example, guided tissue regenerationwith
or without the use of bone supplements has been a well-proven treatmentmodality for the reconstruc-
tion of bony defects prior to the tissue engineering era. Active biomaterials have been subsequently
introduced to the periodontal communitywith supporting dental literature suggesting that certain fac-
tors should be taken into considerationwhen undertaking periodontal regenerative procedures. These
factors as well as a number of other translational research issues will need to be addressed, and ulti-
mately it is vital that we do not extrapolate results from pre-clinical and animal studies without con-
ducting extensive randomized clinical trials to substantiate outcomes from these procedures.
Whatever the outcomes, the pursuit of regeneration of the periodontal tissues remains a goal worth
pursuing for our patients. The aim of the review, therefore is to update clinicians on the recent
advances in both materials and techniques in periodontal regenerative procedures and to highlight
the importance of both patient factors and the technical aspects of regenerative procedures.
 2017 The Authors. Production and hosting by Elsevier B.V. on behalf of King Saud University. This is
an open access article under theCCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).ntistry,
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The general goals of periodontal therapy include: 1. The pri-
mary and secondary prevention of periodontal disease by con-
trolling infection and inflammation and 2. The maintenance
and improvement of the health, function, comfort and aesthet-
ics of all supporting structures and tissues (gingivae, periodon-
tal ligament [PDL], cementum and alveolar bone).
A number of ‘‘so called” pathological entities may neces-
sitate special attention, either because they are considered to
be areas of minoris resistentiae, e.g., intrabony and inter-
radicular defects (Papapanou and Tonetti, 2000), or because
of perceived aesthetic concerns and/or pain to the patients,
e.g., marginal tissue recession defects (Chabanski and
Gillam, 1997). Therefore the ultimate goal for periodontal
treatment is the regeneration of the lost periodontal tissues.
The reconstructive surgery has been one of the most
dynamic therapeutic procedures in periodontology for the
past three decades, and yet, the ultimate goal of regenera-
tion of the periodontal supporting tissues remains unpre-
dictable and challenging.2. Osseous defects
Based on clinical observations and observations on human
skulls bony defects as a result to periodontal disease can be
classified as:
 Suprabony or supracrestal: when the base of the pocket is
located coronal or occlusal to the bone crest,
 Infrabony or subcrestal: when the apical end of the pocket is
located below the bone crest. An infrabony defect may be
subdivided to intrabony defect when the subcrestal compo-
nent involves the root surface of only one tooth and crater
when the defect affects the root surfaces of two adjacent
teeth on an equal extent (Goldman and Cohen, 1958).
An intrabony defect therefore can be sub classified, with
respect to the number of remaining bony walls, in three cate-
gories: the 1-wall, 2-wall and 3-wall defects (Goldman and
Cohen, 1958).
The furcation involvements may also be included in the
group of periodontal bony defects. One of the earliest
Fig. 1 Schematic illustration of the use of GTR in regeneration
of periodontal tissues.
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by Glickman (1953), which was taking into consideration both
the horizontal and vertical dimension of bone loss. Tarnow
and Fletcher (1984) also suggested a classification for the eval-
uation of the vertical component for each type of horizontal
type of furcation defect, measured from the fornix of the fur-
cation area.
Another classification as proposed by Hamp et al. (1975) is
currently the most commonly used classification due to its clin-
ical simplicity:
 Degree I: Horizontal bone loss not exceeding the one third
of the tooth width
 Degree II: Horizontal bone loss exceeding the one third of
the width of the tooth but not involving the total width
of the furcation area
 Degree III: ‘‘Through-and-through” bone destruction
The clinical management of intrabony and furcation defects
may involve a variety of reconstructive periodontal surgical
methods and materials.
3. Biologic foundation of periodontal reconstructive treatment
For the successful reconstruction of periodontal tissues, the
methods that are to be utilised should respect the natural
sequence of biological events that occur during the periodontal
healing and/or mimic the process of tooth and periodontal
tissues embryologic development. Melcher (1976) postulated
on the importance of the different potential of the four
components of the periodontal apparatus in periodontal heal-ing and how the attachment of periodontal tissues to the root
surface was determined by the first type of cells that would
attach to the root surface.
A number of animal studies reported that the rapid epithe-
lial downgrowth (Stahl et al., 1972) on root surfaces inhibited
the connective tissue attachment (Caton and Nyman, 1980). In
addition, when dental implants were placed in contact with
root tips in monkeys, periodontal support consisting of cemen-
tum and connective tissue fibers occurred even on titanium sur-
faces provided that the implants were placed in contact with
vital PDL fibers (Buser et al., 1990a).
The above mentioned experiments and other associated
studies (Bowers et al., 1989; Caton and Nyman, 1980;
McCulloch, 1985; Stahl et al., 1983) appeared to establish that
the bone, the epithelial and gingival connective tissues did not
have any regenerative capacity and that the stem cells, the
immature progenitor cells residing in the PDL, were the cells
with the potential for periodontal regeneration.
4. Guided tissue regeneration
The term guided tissue regeneration (GTR) includes proce-
dures attempting to regenerate lost periodontal tissues when
barrier materials are used to exclude the epithelial and connec-
tive gingival tissues from the root and bone surface (Fig. 1).
Historically various types of membranes have been intro-
duced for the maintenance of the space between the defect
and the root surface in order to enable repopulation of the cells
of PDL and the proliferation and establishment of both PDL
and bone structures. The barrier materials in GTR must there-
fore fulfill five main criteria: 1. Tissue integration, 2. Cell
occlusivity, 3. Clinical manageability, 4. Space-making ability
maintained long enough for both PDL and bone cells to pro-
liferate into the defect and 5. Biocompatibility (non-toxic, non-
antigenic and induce no or little inflammation) (Scantlebury,
1993).
GTR can be performed with the use of nonresorbable and
bioresorbable membranes. The use of non- resorbable mem-
branes has been gradually phased out for the following rea-
sons: (1) a second surgical procedure four to six months
following the initial procedure is necessary for the removal
of the non-resorbable membrane which can be traumatic for
the patient and a risk for the disruption of healing of the newly
formed regenerated tissues; (2) the soft tissue that grows api-
cally on the outside surface of the membrane can potentially
be an area of weakness where both inflammation and marginal
tissue recession may subsequently occur and (3) specific types
of non-resorbable membranes have been associated with early
and spontaneous exposure to the oral environment (Selvig
et al., 1992).
4.1. Membranes
Six resorbable and autologous materials have been successfully
tested for their safety and efficacy in GTR procedures:
4.1.1. Collagen barriers
This type of membrane has been widely used in clinical prac-
tice (i.e. Bio-Gide, Geistlich, Wolhusen, Switzerland) due
to its attractive biologic and physical properties as well as its
commercial availability (Fig. 2a–e). Type I collagen is the
Fig. 2 a. Deep persisting periodontal pocket mesial of the LR6; b. Radiographic signs of angular bone loss mesial of the LR6 and
furcation involvement; c. Alveolar bone defects as revealed following the elevation of a buccal flap; d. Placement of xenograft and collagen
membrane in the defects (Bio-Oss and Bio-Gide respectively); e. Radiographic signs of bone fill mesial and at the furcation area of
LR6.
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would appear therefore to mimic the natural consistency of
the periodontal tissues. Several investigators have suggested
that collagen membranes may have a positive role in the regen-
eration of periodontal tissues (Pitaru et al., 1987). Cross-link
techniques have been used in order to improve the characteris-
tics of these membranes, as for example to prolong their
resorption rate, which may vary from six to eight weeks to
six to eight months. Additional studies however, are required
for the improvement of their properties as it has been demon-
strated that there are limitations in providing/maintaining the
wound space, together with the observation that the amount of
regeneration following their use may be both limited and
unpredictable (Tatakis et al., 1999).
4.1.2. Cargile membranes
They are derived from bovine intestines (ox caecum) and their
resorption rates appear to range from 30 to 60 days. No signif-
icant clinical attachment level (CAL) gain and difficult han-
dling characteristics however have been reported with the use
of cargile membranes (Card et al., 1989).
4.1.3. Polylactic, polyglycolic and polyglactin copolymer acid
barriers
The poly (a-hydroxy) acids are synthetic materials. Their degra-
dation in the humanbody by hydrolysis has been shown to result
in products that are metabolized through the citric acid cycle
(Krebs cycle). These materials have been associated with a loca-
lised decrease of pH and inhibitory effects in osteogenesis. In
addition, due to their slow degradation rate the barrier material
can persist in human body for four to six years and may stimu-
late a late localised foreign-body reaction (Tatakis et al., 1999).
The cross-linking and/or the addition of lactide and/or glycolide(i.e. VICRYL PeriodontalMesh copolymer; Johnson& John-
son NJ, USA; Fleisher et al., 1988) may however result in their
faster degradation. Only a limited number of studies have
demonstrated any clinical efficacy of this group of materials in
GTR procedures (Bremm et al., 2004; Magnusson et al., 1988;
Stavropoulos and Karring, 2004).
4.1.4. Oxidized cellulose mesh barriers
These barrier membranes are made of a resorbable haemo-
static dressing material which has been observed to have
encouraging effects in GTR procedures (Galgut, 1990). How-
ever, it appears to provide with limited wound space and as
such cell exclusion may be high. The acidic nature of the mate-
rial may also be responsible for the delayed healing of the bone
tissue following its use (Tatakis et al., 1999). Additional and
well designed clinical studies of this material are therefore
essential prior to inclusion as barrier membrane in GTR
procedures.
4.1.5. Autogenous periosteal barrier membranes
The use of connective tissue with periosteum collected from the
host’s palate combined with autogenous bone chips would
appear to be a promising combination for use in GTR proce-
dures, as studies have demonstrated superior bone levels’ gain
and less post-operative marginal tissue recession when com-
pared with open flap debridement (OFD) alone (Paolantonio
et al., 2010). More studies than the existing case report studies
are needed for the investigation of these autogenous
membranes.
4.1.6. Laminar bone allograft membranes
The use of this barrier membrane in combination with partic-
ulate demineralized freeze-dried bone allograft (DFDBA) may
30 M. Siaili et al.also be of promise as demonstrated in a randomized clinical
trial (RCT) in patients with twelve pairs of Class II mandibular
molar furcation lesions (Scott et al., 1997). However, further
studies with much higher power are necessary for conclusive
evidence on the use of this material as membrane barrier in
GTR procedures.
4.2. Bone replacement grafts
Various types of grafting materials have been introduced in
reconstructive periodontal treatment based on their ability to
facilitate the reconstruction of the lost supporting apparatus
through the following mechanisms:
 Osteoneogenesis (contain bone-forming cells)
 Osteoconduction (serve as a scaffold and space provision
for bone formation)
 Osteoinduction (contain bone-inducing substances
[Brunsvold and Mellonig, 1993]).
4.2.1. Autografts
Historically Hegedus (1923) published six successfully treated
cases of ‘‘advanced pyorrhea” with the transplantation of
autogenous bone from the tibia to the jaws. Several types of
autogenous grafts have been proposed in the literature:
4.2.1.1. Cortical bone chips. (Nabers, 1984; Nabers and
O’Leary, 1965): One of the problems with this material was
its potential for sequestration and the (average) large particle
size of the chips. As a result other types of autogenous grafts
were preferred (Mellonig, 1992).
4.2.1.2. Osseous coagulum and bone blend (Robinson, 1969).
Compared to open flap debridement alone the use of this auto-
graft in self-contained defects appears to result in improved
levels of clinical attachment after healing.
4.2.1.3. Intraoral cancellous bone and marrow. Conflicting out-
comes from a number of studies on this material make any
interpretation of the results difficult. For example one study
by Rosenberg (1971) reported that there was more than 50%
bone fill following implantation of the material whereas a
study by Renvert et al. (1985) reported that there was just lim-
ited difference between grafted and non-grafted areas, with a
more favourable result in deep sites.
4.2.1.4. Extra-oral cancellous bone and marrow (Schallhorn,
1968). Due to a number of reported problems with the use of
this type of autogenous graft its use in everyday periodontal
practice has limited. Both ankylosis and root resorption may
occur following the use of an iliac graft as well as high morbid-
ity associated with the donor site (Dragoo and Sullivan, 1973;
Ellegaard et al., 1976).
4.2.2. Allografts
The bone allogeneic grafts are usually procured within twelve
hours of the donor’s death and placed in tissue banks. Four
types of allogeneic grafts have been used in periodontal recon-
structive therapy:4.2.2.1. Frozen iliac allograft. has demonstrated favourable
results. However, the need for extensive cross-matching to
decrease the possibility of disease transmission and graft rejec-
tion has limited the widespread use of it in periodontal treat-
ment (Rosen et al., 2000).
4.2.2.2. Freeze-dried bone allograft (FDBA). This type of graft
has been reported to be effective as a scaffold over which new
bone may form (Goldgerg and Stevenson, 1987).
4.2.2.3. Demineralized freeze-dried bone allograft (DFDBA). It
has been reported that hydrochloric acid and freeze-drying of
cortical bone graft may expose the morphogenetic proteins in
the bone matrix, and therefore enhance its osteogenic potential
(Urist and Mikulski, 1979). DFDBA has been considered to be
one of the ‘‘gold standard” grafts in periodontal regeneration,
with favourable outcomes (Libin et al., 1975; Pearson et al.,
1981; Rosen et al., 2000).
The risk of disease transmission has always been a concern
with the use of allografts. However, this may be minimal if the
graft is harvested and processed according to the standards
and guidelines of established bodies (e.g., American Associa-
tion of Tissue Banking) (Mellonig, 1995). In addition, human
studies have shown no immune reaction (antigenicity) follow-
ing treatment with both FDBA and DFDBA (Quattlebaum
et al., 1988).
4.2.3. Xenografts
These grafts demonstrate osteoconductive properties and have
been considered to be risk free of disease transmission. Xeno-
grafts are available in two types:
4.2.3.1. Bovine derived bone replacement grafts. Bovine bone is
processed for the elimination of its organic part leaving a
hydroxyapatite ‘‘skeleton” of a microporous structure of corti-
cal and cancellous bone, similar to that of human body. It has
been suggested that this type of graft acts as an osteoconductive
scaffold and enables bone growth with subsequent integration
with host’s bone (Nasr et al., 1999). Bio-Oss (Geistlich, Wol-
husen, Switzerland) is the most well-known and commercially
available product in this category (Fig.2) and has been associ-
ated with the successful management of intrabony and inter-
radicular defects (Richardson et al., 1999; Taheri et al., 2009).
4.2.3.2. Coralline calcium carbonate. Biocoral (Inoteb, Saint
Gonnery, France) is a resorbable material of calcium carbon-
ate, obtained from a natural coral and it is composed primarily
of anagonite (>98% CaCO3). The porosity of the material
(>45%) is similar to natural bone and does not appear to
require transformation to a carbonate phase, thus allowing
both rapid resorption and bone replacement (Nasr et al.,
1999). A number of studies have demonstrated promising
results with the use of Biocoral in human bony defects
(Gao et al., 1997).
There may however be a risk of rejection of regenerative
treatment with the use of xenografts by patients due to cultural
and religious reasons.
4.2.4. Alloplastic grafts
These materials function primarily as bone fillers (3rd World
Workshop in Periodontics 1996). Synthetic grafts are available
Fig. 3 Tissue engineering in periodontics.
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advantages of unlimited quantity, no risk for disease transmis-
sion and no additional surgical site. Alloplastic grafts can be
divided in four main categories:
4.2.4.1. Polymers. HTR (Bioplant, Norwalk, CT) is a
commercially available synthetic bone of this category. It is a
composite of polymethylmethacrylate, polyhydroxylethyl-
methacrylate and calcium hydroxide and may be considered
to be a non-resorbable material. Human studies have demon-
strated favourable clinical results with the use of HTR and
have reported new bone growth deposition on its hydrophilic
particles (Stahl et al., 1990; Yukna, 1990). Other studies how-
ever, have failed to demonstrate any significant clinical efficacy
for this material (Shahmiri et al., 1992).
4.2.4.2. Tricalcium phosphate (TCP). The most commonly
used form of this material is b-tricalcium phosphate (b-TCP)
which may be considered to be a partially resorbable material
that initially acts as a scaffold for bone formation. A number
of studies have indicated beneficial results in periodontal
reconstruction with the use of tricalcium phosphate (Cutright
et al., 1972; Stein et al., 2009). Other studies however, have
highlighted the tendency of the particles of this material to
be encapsulated by fibrous connective tissue (Baldock et al.,
1985).
4.2.4.3. Hydroxyapatite. This is the dominant mineral compo-
nent of human bone. Synthetic hydroxyapatite has been intro-
duced in three types (Nasr et al., 1999): (i) the dense type,
which is a result of high temperature process, is non porous
and dense (Meffert et al., 1985; Yukna, 1989); (ii) the porous
type, which is a result of the hydrothermal conversion of the
calcium carbonate exoskeleton of the natural coral into the
calcium phosphate hydroxyapatite. The porosity of this mate-
rial facilitates the bone ingrowth into the pores; (iii) the resorb-
able type, which is a result of a low temperature process. Its
slow resorption rate allowed prolonged osteoconductive action
(Ricci et al., 1992). A combination of hydroxyapatite (60%)and b-TCP (40%) is commercially available (Straumann
BoneCeramic). However, long-term studies for the efficacy of
this combined product are currently lacking.
4.2.4.4. Bioactive glass. This material is composed of CaO,
Na2O, SiO2, P2O5 and may be resorbable or non-resorbable,
depending on the relative proportion of its compounds. It
would appear to bond to bone through the development of a
double layer of silica gel and calcium-phosphorous. It has been
suggested that the material promotes the adsorption of pro-
teins by osteoclasts to form an extracellular bone matrix
(Nasr et al., 1999). There are two main types of commercially
available bioactive glasses, the PerioGlas (NovaBone Den-
tal) and BioGran (BIOMET 3iTM). Data from the published
literature appeared to suggest that bioactive glass was effica-
cious in the treatment of intrabony defects (Lovelace et al.,
1998; Mengel et al., 2006; Subbaiah and Thomas, 2011). How-
ever, a histological study of human defects reported that fol-
lowing the use of bioglass, only limited bone formation was
observed and, in the most of the samples, evidence of any
new cementum and inserting collagen fibers formation was
lacking (Nevins et al., 2000). It is possible that different brands
of bioglasses vary in their efficacy and therefore this assump-
tion should be investigated in well conducted RCTs (Sohrabi
et al., 2012).5. Active biomaterials
A relatively new discipline, the tissue engineering in periodon-
tal therapy has been developed in part due to a growing body
of evidence regarding the biologic functions of the human
body. The biological basis for this innovation was based on
the concept that certain factors were able to regulate both,
the differentiation and function of progenitor cells within the
healing wound area (periodontal tissues) which would lead
to a more favourable outcome of new bone, cementum and
PDL formation (Fig. 3).
Three basic elements have been investigated in order to
manipulate the sequence of events that may lead to complete
periodontal healing: (1) stem/progenitor cells, (2) conductive
scaffolds and (3) signaling molecules (Chen and Jin, 2010).
5.1. Stem cells
The term ‘‘stem cells” refers to clonogenic, undifferentiated
cells that are capable of self-renewal and multi-lineage differ-
entiation depending on their intrinsic signals that can be regu-
lated by extrinsic factors (Lin et al., 2008). In general terms the
molecular signals which can control differentiation of cells
include soluble factors (e.g., hormones and cytokines), matrix
molecules, direct cell to cell contacts and external stimuli (e.g.,
mechanical stimulation) (Hughes, 1995).
Stem cells are categorized in embryonic and adult (somatic)
cells. Hematopoietic stem cells from bone marrow have been
identified first and were already in use for therapeutic pur-
poses. Bone marrow stromal cells (BMSSCs) or mesenchymal
stem cells (MSCs) are a different population of stem cells that
has been identified in the adult body. It appears that all the tis-
sues with tendency for renewal contain at least a small number
of stem cells (Lin et al., 2008).
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result laid the foundation for the development of novel strate-
gies for periodontal reconstruction. A key determinant of the
regenerative potential of the PDL was the ability of stem cells
to undergo specialised osteoblast and cementoblast differenti-
ation, resulting in new bone and cementum formation.
5.2. Conductive scaffolds
The wound healing process occurs within in a three-
dimensional environment, the extracellular matrix (ECM) that
facilitates the molecule regulation of the cells activity. It is
therefore evident that, in regenerative procedures an artificial
tissue-engineering scaffold is an essential prerequisite in order
to facilitate bone formation, etc. (Chen and Jin, 2010). A
matrix may assist the penetration, attachment, proliferation,
differentiation and in-growth of cells that are necessary for
regeneration and inhibit the infiltration of undesirable cells
on the healing site. The biomaterial scaffold, like the natural
biological tissues should be viscoelastic and have an ‘‘ideal”
porosity for cell in-growth, adequate surface area (bioavail-
ability), adequate mechanical strength and favourable degra-
dation (biodegradable) properties (Ahmed et al., 2008).
Biomaterial scaffolds may be fabricated from either natural
materials (i.e., collagen and fibrin) or from synthetic materials
(i.e., polyglycolide and polylactide polymers and copolymers).
These materials may also be designed with a microstructure
that has the ability to release molecules to induce and acceler-
ate the periodontal regeneration cascade events (Chen and Jin,
2010). Further research however is required for the develop-
ment of the ideal conductive scaffold for periodontal regener-
ation, based on tissue engineering techniques.
5.3. Signaling molecules/growth factors
The carefully controlled coordinated expression of a range of
growth factors directs the osteoblastic commitment of MSCs,
the proliferation and clonal amplification of progenitor cells,
and ultimately the production and release of bone related
ECM. Additionally, the activity of a number of these growth
factors is further regulated by the production of antagonistic
inhibitor molecules which may block their activities
(Hughes et al., 2006). In view of the importance of these factors
during bone formation, there is continuing research into their
therapeutic potential to stimulate tissue regeneration, as briefly
discussed below:
5.3.1. Platelet-rich plasma
Platelet-rich plasma (PRP) is an autologous concentration of
platelets in plasma, developed by gradient density centrifuga-
tion of patient’s blood. PRP contains many growth factors,
e.g., platelet- derived growth factor (PDGF) and transforming
growth factor-b (TGF-b) (Del Fabbro et al., 2011). Two recent
multicenter RCTs on the use of recombinant human PDGF
(rhPDGF) in combination with b-TCP in intrabony defects
demonstrated that the adjunctive use of rhPDGF resulted in
an improvement in CAL gain and greater reduction in probing
depths (PD) compared to the sole use of b-TCP (Jayakumar
et al., 2011; Nevins et al., 2005). Investigators have also
reported encouraging results from the use of PRP in combina-
tion with bovine derived xenograft in the treatment ofintrabony defects (Ouyang and Qiao, 2006). However, in the
treatment of furcation defects (Class II), PRP gel appeared
to have only a limited role (Pradeep et al., 2009). Although
there is no convincing evidence for its use in periodontal regen-
eration procedures it would appear that PRP can be advanta-
geous if used as an adjunct to grafting procedures in the
treatment of intrabony defects, but not in combination with
GTR. PRP has also been used for bone augmentation proce-
dures in implantology (Zeckner et al., 2003).
5.3.2. Bone morphogenetic proteins
Bone Morphogenetic Proteins (BMPs) form a unique group of
proteins within the Transforming Growth Factor beta (TGF-
b) superfamily. BMPs demonstrate chemotactic properties
and, depending on their concentration gradient, they may also
function as mitogenic factors or induce the differentiation of
mesenchymal progenitor cells into chondroblasts and osteo-
blasts. BMPs may therefore have a regulatory effect on bone
morphogenesis (Sykaras and Opperman, 2003). Further
in vivo experimentation may therefore help to precisely deter-
mine the therapeutic significance of these molecules
5.3.3. Cell-binding peptide
This is a synthetic clone of a specific acid sequence of Type I
collagen, which has been reported to be involved in the binding
of cells, e.g., osteoblasts and fibroblasts (Yukna et al., 2000).
PepGen P-15 is a product that has been tested in conjunction
and compared to an organic bovine-derived hydroxyapatite
bone matrix and demonstrated positive effects on periodontal
regeneration (Yukna et al., 2000). Further studies however are
necessary before more definitive conclusions can be made on
P-15 peptide’s efficacy.
5.3.4. Fibroblast growth factor
Fibroblast growth factor-2 (FGF-2) is a member of the hep-
arin binding growth factor family and has been demonstrated
to promote the proliferation and attachment of endothelial
and PDL cells in wound healing. In a recent multicenter
RCT, the use of FGF-2 produced by genetic recombination
that transformed Escherichia coli with the human gene
FGF-2 was evaluated in the treatment of vertical bony defects
resulting in improved CAL (Kitamura et al., 2011).
5.3.5. Enamel matrix derivatives (EMD)
EMD were developed to induce regeneration by mimicking the
process that occurs during the development of the root and the
periodontal tissues. Specifically they mimic the critical point in
tooth development when the inner cells of Hertwig’s epithelial
root sheath secrete enamel matrix proteins which are subse-
quently deposited onto the root surface initiating a cascade
of actions that would eventually lead to cementum creation,
PDL and bone formation. However, the underlying mecha-
nisms for the precise role of EMD on the cellular and molecu-
lar level are not well understood even though products
containing EMD are commercially available (Emdogain,
Straumann, Basel, Switzerland) with approximately fifteen
years of supportive clinical and histological data.
Hammarstrӧm (1997) published one of the first studies that
included histological results following the use of EMD in buccal
dehiscences in monkeys and reported up to 70% of new
Fig. 4 a. Deep persisting periodontal pocket mesial and distal of the LL6; b. Radiographic signs of angular bone loss mesial and distal of
the LL6 and furcation involvement; c. Alveolar bone defects as revealed following the elevation of a buccal flap; d. Placement of enamel
matrix derivatives combined with alloplastic graft (Straumann Emdogain PLUS) in the defects; e. Radiographic signs of bone fill
mesial, distal and at the furcation area of LL6.
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regenerative procedure. Encouraging results were also pub-
lished when EMD was applied in intrabony defects’ areas and
resulted in partial (66%) bone fill (Heijl et al., 1997; Fig. 4a–
e). The use of EMD in the treatment of Class II mandibular fur-
cation defects was also tested and resulted in a higher rate of
Class II to Class I conversion (Casarin et al., 2008).
A Cochrane meta-analysis reported that the application of
EMD showed statistically significant improvements in both
CAL and PD reduction when compared to OFD or placebo
(Esposito et al., 2009). One problem in evaluating the potential
of EMD is that only short-term studies are currently available. It
is therefore essential that further long term studies evaluating
the material’s efficacy in regenerative procedures compared to
established treatment modalities are initiated in well controlled
RCTs.
A number of published clinical studies have reported on
root conditioning of the root surfaces with ethylenediaminete-
traacetic acid (EDTA) in conjunction with the application of
EMD. It was concluded that the adjunctive use of EDTA
failed to demonstrate any statistically significant differences
in CAL gain and PD reduction in intrabony defects and that
the benefits from using this chelating agent in EMD
application remained to be clarified in further studies
(Parashis et al., 2006; Sculean et al., 2006).6. Case selection and treatment considerations
The predictability of reconstructive procedures in osseous
defects may be dependent upon a variety of associated
factors:6.1. The patient
Socioeconomic and behavioural factors have to be taken into
consideration when planning a surgical procedure, as they
may affect the ability of the patient to protect and maintain
the results of the treatment. For example, cigarette smoking
has been demonstrated to prevent new tissue growth and bone
formation following GTR in mandibular molars (Machtei
et al., 2003). A recent meta-analysis also highlighted the nega-
tive effect of smoking in the bone regeneration of intrabony
defects (Patel et al., 2012). Diabetic patients may also demon-
strate impaired response to periodontal therapy (Grossi et al.,
1996). However, evidence regarding the response to regenera-
tive procedures in patients with diabetes is limited at the pre-
sent time in the published literature.
6.2. The site
Cortellini et al. (1998) in a multicenter RCT evaluated the effi-
cacy of GTR with bioabsorbable barrier membranes, com-
pared to OFD surgery in intrabony defects. The results
indicated that GTR with bioabsorbable membranes resulted
greater linear amounts of improvement in deep than shallow
defects, with similar potential of CAL gains expressed in per-
centages. Wider defects (22) have been however associated
with less beneficial results following reconstructive therapy
(Cortellini and Tonetti, 2000; Tsitoura et al., 2004). The num-
ber of residual bony walls may be considered as a factor that
may subsequently affect the choice of the regenerative method
and material. Investigators however have failed to demonstrate
any significance of the number of bony walls of a treated
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the treatment of intrabony defects with an unfavorable archi-
tecture (one-wall, shallow and wide), may be effective
(Aimetti et al., 2005). Class III furcation defects have been
considered to be very challenging in reconstructive therapy
due to an unfavorable response (Pontoriero and Lindhe,
1995). The existence of root trunk concavities may also influ-
ence the outcome of regenerative procedures, with the need
to modify the membrane used to allow better adaptation and
provide a more satisfactory therapeutic result (Villaça et al.,
2004). Bowers et al. (2003), with a prospective study demon-
strated that the horizontal and vertical probing depths at the
furcation areas need to be evaluated as they have been shown
negatively associated with complete closure of the defects.
According to the investigators, the root divergence in addition
to the interproximal bone height in conjunction to the position
of the fornix of the furcation are three parameters that also
need to be assessed as they may affect the result of regenerative
procedures in furcation defects.
6.3. The procedure and the healing period
Bone defects should be filled by the bone replacement grafts to
a realistic level that will allow for primary closure of the flaps.
Both the flap adaptation and primary closure are of critical
importance in reconstructive therapy, for example in prevent-
ing possible exposure and contamination of the regenerative
materials. Excellent plaque control during the healing phase
is also crucial for a more positive regenerative response
(Machtei et al., 1994). A recent in vitro study, based on the
rationale of the importance of wound stability during healing,
evaluated the efficacy of EMD under biomechanical loading.
The results would suggest that occlusal loading may jeopardize
the beneficial actions of EMD (Nokhbehsaim et al., 2011).7. Discussion
Defects concerning the tooth supporting tissues may lead to
impairments in the functioning, aesthetics and/or the ability
of a person to maintain a stable periodontal status. A rapid
development in both innovative methods and products for
the correction of periodontal deficiencies has been reported
during the last three decades. For example, guided tissue
regeneration with or without the use of bone supplements
has been a well-proven treatment modality for the reconstruc-
tion of bony defects prior to the tissue engineering era. Active
biomaterials have been subsequently introduced to the peri-
odontal community with supporting dental literature that
has suggested that certain factors should be taken into consid-
eration when undertaking periodontal regenerative proce-
dures. According to Cortellini and Bowers (1995) specific
factors such as patient characteristics, the morphology of the
defect, and the planned surgical technique may influence the
healing response of intrabony defects. The issue of patient
compliance, the ability to maintain good oral hygiene and
the influence of smoking may also affect the predictability of
periodontal regeneration. It is also important to acknowledge
that the shape of the defect may be critical, for example, deep
and narrow defects have been reported to respond favorably to
regenerative procedures (Cortellini and Bowers, 1995).Furthermore, the technical aspect of such procedures should
not be ignored for example, flap design, defect debridement,
handling of the soft tissues and wound protection, Periodontal
regeneration has therefore, been considered as the ultimate and
yet unmet goal of modern periodontal treatment. GTR, with
and without the use of bone grafting materials appears to be
the gold standard on the reconstruction of intrabony and inter-
radicular defects for more than one decade (Needleman et al.,
2005). However, with the development of the tissue engineer-
ing science various biomaterials have been introduced for clin-
ical use. EMD has the most long-standing evidence in
comparison to other biomaterials and demonstrated similar
efficacy with the GTR techniques (Esposito et al., 2009). The
combination of different materials also seemed to be appealing
and in some studies demonstrated encouraging results
(Trombelli and Farina, 2008). A number of factors, concerning
the patient and the surgical site have to be correctly evaluated
prior to the application of any regenerative procedure and to
be strictly controlled during the postoperative healing period.
The periodontist should therefore, aim for a better understand-
ing of the available materials and techniques so they can apply
the developing knowledge in the clinical environment with suc-
cessful outcomes.
8. Conclusions
The periodontal regeneration of intrabony defects not only
involves the experience and skills of the clinicians but also
the selection of the suitable regenerative materials and tech-
niques from the dental armamentarium. A variety of surgical
techniques and products for regeneration have been available
with substantial research evidence reporting on their efficacy.
The clinician should make their choice for the best suitable
regenerative modality based on general and site specific factors
and with respect to the natural healing events occurring post
operatively.
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Clinical relevance
A large number of surgical techniques and products have been
developed for the reconstruction of the lost periodontal tissues.
The clinician should be aware of the evidence for supporting
each of the available regenerative modalities so they can make
the best possible decision for the achievement of a successful
outcome in day-to-day clinical practice.
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